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Clofibrate, a peroxisome proliferator-activated receptor-a
(PPARa) agonist, increases renal tubular cytochrome
P450 4a (Cyp4a) expression thereby increasing
20-hydroxyeicosatetraenoic acid (20-HETE) production. To
determine if clofibrate affects blood pressure regulation
we studied mice with DOCA-salt induced hypertension in
wild-type and PPARa knockout mice. Wild-type mice treated
with DOCA-salt had higher mean arterial pressures and
higher cumulative sodium balance, but lower renal 20-HETE
production than did vehicle-treated mice. Treating DOCA-salt
mice with clofibrate attenuated the increase in mean arterial
pressure and cumulative sodium balance while increasing
20-HETE production and renal Cyp4a expression. In contrast
the PPARa knockout mice treated with clofibrate and
DOCA-salt showed no attenuation in the increase of blood
pressure, cumulative sodium balance, renal 20-HETE
production or Cyp4a protein expression. Expression of
the PPARa protein was greater in proximal tubules than in
renal microvessels. Our results show that PPARa pathway
induces renal tubular 20-HETE production which affects
sodium retention and blood pressure regulation in
DOCA-salt-treated mice.
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20-Hydroxyeicosatetraenoic acid (20-HETE), the o-hydro-
xylation product of arachidonic acid (AA), is a principal
eicosanoid in renal vasculatures and tubules, including the
proximal tubules and the thick ascending limb of the loop of
Henle (TALH). Synthesis of 20-HETE is primarily catalyzed
by the cytochrome P450 (Cyp) 4a gene family.1 In the mouse,
four isoforms have been identified: Cyp4a10, Cyp4a12a,
Cyp4a12b, and Cyp4a14. Using baculovirus and Sf9 insect
cells, Muller et al.2 in a study of the hydroxylation of AA
by mouse Cyp4a isoforms, have demonstrated that AA
o- hydroxylation is catalyzed by Cyp4a10, Cyp4a12a, and
Cyp4a12b. Cyp4a12a and Cyp4a12b have similar catalytic
activity for 20-HETE production, with a Vmax value of
about 10 /min and a Km value of about 20–40 mM.
2 The
o-hydroxylase activity of AA for Cyp4a10 is about 25 to
75-fold lower than that of Cyp4a12 isoforms. These results
suggest that Cyp4a12 isoforms constitute the major source of
20-HETE synthesis. In the renal vasculature, 20-HETE
promotes vasoconstriction and contributes to myogenic
tone.3,4 In renal tubular segments, 20-HETE is an important
mediator in the regulation of sodium transport. For example,
20-HETE inhibits proximal tubular Naþ -Kþ -ATPase acti-
vity5 and TALH Naþ -Kþ -2Cl co-transporter activity;6 it
also blocks TALH renal outer medulla Kþ channel activity.7
Many investigators have found that 20-HETE is important in
regulating blood pressure in animal models and hypertensive
patients.1,8
Peroxisome proliferator-activated receptor a (PPARa) is a
nuclear hormone-activated transcription factor that regulates
the expression of other genes by binding to specific
peroxisome proliferator response elements in the promoter
region of the targeted genes.9 PPARa upregulates many genes
such as acyl-CoA oxidase and carnitine palmitoyl transferase
I that are involved in fatty acid oxidation.10 PPARa, which
is highly expressed in the kidney, liver, heart, and digestive
tract,11 is the target for fibrate drugs, which lower triglyceride
levels in dyslipidemic patients. Many fatty acids and eicosa-
noids also act as important endogenous ligands for
PPARa.12,13 In addition, the fact that peroxisome proliferator
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response elements are found in the promoter regions of
cyp4a genes indicates that PPARa has a prominent function
in the regulation of cyp4a expression.14,15 Moreover,
clofibrate reduces blood pressure in hypertensive animal
models.16–18
The mineralocorticoid receptor (MR) is highly expressed
in renal collecting ducts, where it regulates sodium reabsorp-
tion. The MR has much higher affinity to aldosterone than it
does to cortisol.19,20 However, in active circulation, the
concentration of cortisol (1 mM) is much higher than that of
aldosterone (1 nM).21 To prevent excess activation of MR by
the abundant cortisol, microsomal 11b-hydroxysteroid dehy-
drogenase type 2, which catalyzes the conversion of cortisol
to cortisone, is highly expressed in renal distal tubules.
Cortisone has very low binding affinity to MR.21 Hyper-
aldosteronism is associated with excess activation of MR and
is characterized by abnormally elevated aldosterone secretion,
which is linked to sodium retention and hypertension.
Similarly, mutations in 11b-hydroxysteroid dehydrogenase
cause a mineralocorticoid excess syndrome that includes
sodium retention and hypertension.22 The use of a synthetic
mineralocorticoid, DOCA, which is an aldosterone analog,
together with a high-salt diet (DOCA-salt), is a well-esta-
blished means of inducing hypertension in mice. DOCA-salt
hypertension is mediated through the stimulation of sodium
retention in renal collecting ducts.23 Thus, the DOCA-salt
mouse is a model that mimics hyperaldosteronism. In this
study, we examined the influence of PPARa activation on
renal 20-HETE production and Cyp4a expression, sodium
retention, and blood pressure in wild-type mice and mice
with PPARa(/) treated with DOCA-salt.
RESULTS
Effect of clofibrate on blood pressure and sodium balance
in wild-type mice and mice with PPARa(/)
To determine the effect of clofibrate on blood pressure, we
treated 5-week-old uni-nephrectomized male wild-type mice
and mice with PPARa(/) with vehicle, DOCA-salt, or
DOCA-salt plus clofibrate. Mean arterial pressure (MAP) was
significantly higher in the DOCA-salt group than in the
vehicle control group in both wild-type mice and mice
with PPARa(/) (Figure 1). Administration of clofibrate
significantly inhibited the increase in MAP produced by
DOCA-salt treatment in wild-type mice, but not in mice with
PPARa(/) (Figure 1).
To determine whether clofibrate has any effect on sodium
retention, we measured the cumulative sodium balance
for 14 days in 5-week-old wild-type mice and mice with
PPARa(/) that were given different treatments. On the
14th day of measurement, cumulative sodium balance was
significantly increased (0.8±0.01 mEq) in DOCA-salt-treated
wild-type mice as compared to that in the vehicle-treated
control group (0.25±0.04 mEq) (Figure 2a). A similar in-
crease in cumulative sodium balance occurred in mice with
PPARa(/) treated with DOCA-salt (Figure 2b). Interest-
ingly, treatment of wild-type mice with a combination of
clofibrate and DOCA-salt caused the cumulative sodium
balance to return to the level in the vehicle-treated group,
whereas in mice with PPARa(/), treatment with DOCA-
salt and clofibrate did not affect cumulative sodium balance
(Figure 2).
Effect of clofibrate on renal Cyp4a expression and 20-HETE
production in wild-type mice and mice with PPARa(/)
To determine whether clofibrate has any effect on renal Cyp4a
expression, we treated 5-week-old wild-type mice and mice
with PPARa(/) with vehicle, DOCA-salt, or DOCA-salt
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Figure 1 | Mean arterial pressure (MAP) in wild-type (n¼ 9)
mice and mice with PPARa(/) (n¼ 5) treated with
vehicle, clofibrate (500 mg/kg/day, intragastrically (i.g.),
DOCA-salt, or DOCA-saltþ clofibrate (500 mg/kg/day, i.g.) for
2 weeks. Values are means±s.e. *Po0.05 versus vehicle control;
#Po0.05 versus DOCA-salt.
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Figure 2 | Effect of DOCA and clofibrate on sodium balance in
wild-type and PPARa(/) mice. Cumulative sodium balance
in (a) wild-type (n¼ 5) mice and (b) mice with PPARa(/)
(n¼ 5) treated with vehicle, DOCA-salt, or DOCA-saltþ clofibrate
(500 mg/kg/day, i.g.) for 2 weeks. Values are means±s.e.
*Po0.05 versus vehicle control; #Po0.05 versus DOCA-salt.
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plus clofibrate. DOCA-salt treatment did not significantly
affect the expression of Cyp4a isoforms in either wild-type
mice or mice with PPARa(/) (Figure 3a). Combining clo-
fibrate with DOCA-salt significantly induced Cyp4a expres-
sion in the kidneys of wild-type mice, but did not affect the
expression of renal Cyp4a in mice with PPARa(/) (Figure
3a). Densitometry analysis normalized with b-actin showed
that, compared with values in the control group, DOCA-salt
treatment did not affect the expression of renal Cyp4a in
wild-type mice. However, clofibrate caused the expression of
Cyp4a to increase about threefold in wild-type mice treated
with DOCA-salt (Figure 3a). In mice with PPARa(/),
treatment with DOCA-salt and clofibrate did not affect the
expression of renal Cyp4a proteins (Figure 3a).
To determine the effect of clofibrate on renal 20-HETE
production, we examined renal AA o-hydroxylase activity by
HPLC, and found that DOCA-salt treatment caused
decreases in o-hydroxylase activity of 36 and 32%, respec-
tively, in the kidneys of wild-type and PPARa(-/-) mice. In
addition, the administration of clofibrate with DOCA-salt
increased renal o-hydroxylase activity by 100% in wild-type
mice treated with DOCA-salt, but did not affect renal
o-hydroxylase activity in mice with PPARa(/) treated
with DOCA-salt (Figure 3b).
To substantiate these results, we immunohistochemically
analyzed mouse Cyp4a expression in renal sections from
wild-type mice and mice with PPARa(/) treated with
vehicle, DOCA-salt, or DOCA-salt plus clofibrate. The most
intense staining occurred in renal tubules, whereas glomeruli
had a very low immunoreaction to mouse Cyp4a proteins
(Figure 4a). DOCA-salt treatment did not have a significant
effect on the expression of mouse Cyp4a as compared with
Cyp4a levels in control groups of wild-type mice and mice
with PPARa(/). Clofibrate treatment caused increased
Cyp4a expression in renal tubules of wild-type mice, but did
not affect Cyp4a expression in mice with PPARa(/)
(Figure 4a).
In a further exploration of the induction effect of
clofibrate through the PPARa pathway in the kidneys, we
used western blot analysis to examine PPARa expression
in proximal tubules and renal microvessels isolated from
wild-type mice. We detected strong PPARa expression in
the proximal tubules, but very low expression in the renal
microvessels of wild-type mice (Figure 4b).
To determine the effects of DOCA-salt and clofibrate
treatment on the expression of renal Cyp4a mRNAs, we
used real-time reverse-transcription (RT) PCR to examine
the levels of Cyp4a10, 4a12a, 4a12b, and 4a14 in wild-type
mice treated with vehicle, DOCA-salt, or DOCA-salt plus
clofibrate. In wild-type mice, DOCA-salt treatment caused
increased expression of Cyp4a10 and Cyp4a14 mRNAs, but
decreased expression of Cyp4a12a and Cyp4a12b mRNAs
(Figure 5). Combined treatment with DOCA-salt and
clofibrate caused significant elevation of the expression of
Cyp4a10, Cyp4a12a, Cyp4a12b, and Cyp4a14 mRNAs
(Figure 5).
In a complementary experiment, we treated 5-week-old
male wild-type mice and mice with PPARa(/) with
vehicle or clofibrate for 2 weeks. Clofibrate treatment did not
affect MAP in wild-type mice (119±1 versus 120±2 mmHg,
n¼ 5) and in mice with PPARa(/) (120±1 versus
119±2 mmHg, n¼ 5). Clofibrate treatment significantly
induced renal Cyp4a expression (Figure 6a) and 20-HETE
production (Figure 6b) in wild-type mice, but did not affect
renal Cyp4a expression and 20-HETE production in mice
with PPARa(/) (Figure 6).
Effect of clofibrate on 20-HETE production and Cyp4a
expression in primary proximal tubular cells
20-HETE is highly produced in proximal tubules.24,25 As it is
still not clear whether clofibrate can induce proximal tubular
Cyp4a expression in mice, we determined the effects of
clofibrate on the expression of Cyp4a in primary proximal
tubular cells isolated from wild-type mice and mice with
PPARa(/). Incubation of renal proximal tubular cells
isolated from wild-type mice with [14C]-AA and NADPH
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Figure 3 | Impact of DOCA and clofibrate on renal Cyp4a
expression and 20-HETE production. Effect of clofibrate on the
expression of renal Cyp4a (a) and arachidnoic acid o-hydroxylase
activity (b) in wild-type mice and mice with PPARa(/)
treated with vehicle, DOCA-salt, or DOCA-saltþ clofibrate
(500 mg/kg/day, i.g.) for 2 weeks. Numbers at the top of panel A
are arbitrary units of the density ratio of Cyp4a and b-actin
immunoreactive bands (n¼ 3). Values are means±s.e.
*Po0.05 versus vehicle control; #Po0.05 versus DOCA-salt.
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produced very low amounts of 20-HETE and epoxyeicosa-
trienoic acids (black line, Figure 7a). Treatment with clo-
fibrate (50 mM) significantly increased 20-HETE production
(red line, Figure 7a). The activity of 20-HETE production in
proximal tubular cells treated with clofibrate (50 mM) was
about four-fold higher than that in vehicle-treated cells
(16±3 versus 3.7±0.2 pmol/h/106 cells, n¼ 3). Moreover,
clofibrate treatment (20–100 mM) caused dose-dependent
increases in the expression of Cyp4a proteins in proximal
tubular cells from wild-type mice. However, the same
concentrations of clofibrate (20–100 mM) did not affect the
expression of Cyp4a proteins in proximal tubular cells from
mice with PPARa(/) (Figure 7b).
DISCUSSION
DOCA-salt animal models have been used to mimic
hyperaldosteronism, an important factor in the causation
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Figure 4 | Effect of DOCA and clofibrate on Cyp4a expression in renal section and renal tissue distribution of PPARa. Panel
(a) immunohistochemical analysis of mouse Cyp4a in renal section from wild-type mice and mice with PPARa(/) treated with vehicle,
DOCA-salt, or DOCA-saltþ clofibrate (Clof). The expression of mouse Cyp4a proteins was detected by diaminobenzidine (brown). The same
procedure was used for negative control slides, but they were not incubated with primary antibody. Panel (b) shows the distribution
of PPARa in renal microvessels and proximal tubules of wild-type mice. Representative immunoblots of PPARaand b-actin in renal
microvessels and proximal tubules are shown.
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Figure 5 | Quantitive expression of renal Cyp4a mRNAs
in wild-type mice treated with vehicle, DOCA-salt, or
DOCA-saltþ clofibrate as determined by real-time RT-PCR.
Threshold cycles of Cyp4a isoforms were normalized to the18S
rRNA housekeeping gene (DCT) and compared to the levels of each
Cyp4a isoform in the vehicle-treated control group. n¼ 3 for each
group. *Po0.05 versus vehicle control; #Po0.05 versus DOCA-salt.
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of hypertension.23 It has been demonstrated that DOCA-salt
can cause abnormalities in sodium reabsorption, resulting
in the elevation of blood pressure.23 As 20-HETE regulates
sodium transport in nephron segments1 and activation of
PPARa by clofibrate reduces blood pressure in different
hypertensive animal models,17,18 we hypothesized that
increased 20-HETE production by PPARa activation is
also involved in the regulation of blood pressure and
sodium retention in a DOCA-salt model. We found that
DOCA-salt caused hypertension, which was associated with
sodium retention in both wild-type mice and mice with
PPARa(/). The activation of PPARa by clofibrate resulted
in the reduction of blood pressure and sodium retention in
wild-type mice treated with DOCA-salt. In contrast,
clofibrate did not affect either blood pressure or sodium
retention in mice with PPARa(/) treated with DOCA-salt.
These results demonstrate that PPARa activation attenuates
DOCA-salt-induced hypertension through the reduction of
sodium retention.
In addition, we showed that the administration of DOCA-
salt and clofibrate induced the expression of renal Cyp4a
isoforms and 20-HETE production in wild-type mice, but
not in mice with PPARa(/). These findings suggest the
possibility that the effects of clofibrate on sodium retention
and blood pressure regulation in DOCA-salt mice are
associated with the induction of renal 20-HETE production.
However, the results shown in Figure 6 do not support that
possibility; clofibrate induced renal Cyp4a isoforms and 20-
HETE production, but did not decrease the blood pressure of
control mice (119±1 versus 120±2 mmHg, n¼ 5). It is not
yet clear why increased renal 20-HETE production by
clofibrate treatment decreased the MAP of DOCA-salt-
treated mice (Figure 1), but did not affect the MAP of
control mice. This question will require further investigation.
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Figure 6 | Impact of clofibrate on renal Cyp4a expression
and 20-HETE production. Effect of clofibrate on the expression
of renal Cyp4a (a) and arachidnoic acid o-hydroxylase activity
(b) in wild-type mice and mice with PPARa(/) treated with
vehicle or clofibrate (500 mg/kg/day, i.g.) for 2 weeks. Numbers
at the top of panel A are arbitrary units of the density ratio of
Cyp4a and b-actin immunoreactive bands (n¼ 3). Values are
means±s.e. *Po0.05 versus vehicle control.
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Figure 7 | Effect of clofibrate on renal 20-HETE production and
Cyp4a expression in the primary proximal tubular cells
isolated from wild-type mice and mice with PPARa(/).
(a) Representative reverse-phase HPLC elution profile of
metabolites formed during incubation of AA with proximal
tubular cells isolated from wild-type mice (n¼ 3) treated with
either vehicle (0.02% DMSO solution) or clofibrate (50 mM). The
HPLC profile of vehicle-control cells is shown as a black line; that
of clofibrate-treated cells is shown as a red line. (b) Representative
western blots of Cyp4a isoforms by different concentrations of
clofibrate (20–100mM) in proximal tubular cells isolated from
wild-type mice and mice with PPARa(/).
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Many reports support the notion that the production of
renal 20-HETE is catalyzed by CYP4a isoforms in rats and
mice. In rats, recombinant CYP4A1 displayed the highest
o-hydroxylase activity.26 Recombinant CYP4A2 and CYP4A3
exhibit a catalytic activity to 20-HETE that is 10–40 times
lower than that of CYP4A1.26 Similarly, mouse recombinant
Cyp4a12a and Cyp4a12b have very high o-hydroxylase
activity, whereas the catalytic activity of mouse recombinant
Cyp4a10 is much lower than that of Cyp4a12 isoforms.2
Here, we showed that chronic clofibrate treatment can
increase renal 20-HETE production, which is correlated with
the induction of mouse Cyp4a expression in wild-type mice
treated with DOCA-salt (Figure 3). Benzafibrate, a PPARa
agonist, has been demonstrated to have a similar effect on
renal Cyp4a expression in DOCA-salt mice.27 Our real-time
RT-PCR results showed that clofibrate significantly increased
the expression of renal Cyp4a10, 4a12a, 4a12b, and 4a14
(Figure 5). Similarly, fenofibrate, another PPARa agonist, has
been shown to induce the expression of renal Cyp4a10, 4a12,
and 4a14 in mice.28 Taken together, these results provide
solid evidence that the treatment of PPARa agonists induces
Cyp4a expression and increases 20-HETE production in
mouse kidneys.
Our demonstration that DOCA-salt treatment causes a
decrease in renal microsomal AA o-hydroxylase activity in
Sv129 mice is in accord with the finding of Honeck et al.27
that DOCA-salt treatment is associated with decreased renal
o-hydroxylase activity in NMR1 mice. However, these
investigators found that the decreased renal o-hydroxylase
activity was linked to decreased expression of renal Cyp4a
proteins, whereas we did not observe a change in the
expression of Cyp4a proteins in DOCA-salt-treated wild-type
mice (Figure 3). Although the reason for this inconsistency is
not known, it could be the sources of the antibody. The
antibody we used for the western blot analysis was obtained
from Abcam, whereas Honeck et al. obtained their antibody
from Daiichi Chemicals. The difference could also be a
consequence of the use of different strains of mice (Sv129
versus NMR1). Different expression patterns of renal CYP4A
isoforms have been demonstrated in different strains of
rats.29 It is also possible that the absence of change in Cyp4a
expression in response to DOCA-salt treatment (Figure 3a) is
a consequence of the fact that such treatment increases the
expression of some Cyp4a isoforms, but decreases the
expression of others. As shown in Figure 5, DOCA-salt
treatment induced the expression of Cyp4a10 and Cyp4a14,
but inhibited the expression Cyp4a12a and Cyp4a12b as
shown by real-time RT-PCR analysis, supporting this
possibility.
It is also interesting to note that DOCA-salt caused the
downregulation of Cyp4a12a and 4a12b in wild-type mice
(Figure 5). This may be the reason for the decreased produc-
tion of 20-HETE in DOCA-salt-treated mice (Figure 3b).
Cyp4a12 isoforms have much higher catalytic activity for
20-HETE production than Cyp4a10 and Cyp4a14.2 Although
this study, like others,27 showed that DOCA-salt treatment
caused decreased production of renal 20-HETE in mice,
Oyekan et al.30 found that DOCA-salt treatment caused
a four-fold increase in urinary 20-HETE excretion in rats.
The reason for the opposite effects of DOCA-salt on renal
20-HETE production in mice and rats is not known.
This study showed that DOCA-salt caused sodium
retention and hypertension in both wild-type mice and
mice with PPARa(/) (Figures 1 and 2). These results
agree with the theory that the administration of DOCA and a
high-salt diet can cause an increase in sodium reabsorption
in the collecting ducts, thereby causing sodium retention
and hypertension.23 Tomita et al.31 showed that chronic
administration of DOCA to rats caused a 30-fold increase
in sodium retention in perfused cortical collecting ducts.
Our study demonstrated that chronic administration of
clofibrate resulted in the reduction of sodium retention
in wild-type mice, but did not affect sodium retention
in mice with PPARa(/) (Figure 2). These results
make it clear that the activation of PPARa is extremely
important in regulating renal sodium transport in DOCA-
salt mice.
It is questionable, however, whether the increase of renal
20-HETE in response to clofibrate treatment can affect
sodium transport in the collecting ducts. Several reports have
shown that PPARa is mainly expressed in the proximal
tubules and TALH. For example, using western blot analysis,
Ishizuka et al.32 showed that PPARa protein is expressed in
the proximal tubules and TALH, but not in the collecting
ducts. Similarly, Gyan et al.33 showed that PPARa mRNA is
predominantly expressed in the proximal tubules and TALH
of rabbits and humans. Based on these findings, it is possible
that the increase of 20-HETE levels by clofibrate attenuates
sodium retention as a consequence of the actions of 20-HETE
on sodium transport in the proximal tubules and TALH. For
example, 20-HETE inhibits both renal Naþ -Kþ -ATPase
activity5 and sodium transport in isolated perfused rabbit
proximal tubules.34 Previous studies have demonstrated that
in TALH 20-HETE inhibits Naþ -Kþ -2Cl co-transporter
and Kþ channels.6,7,35 Interestingly, we found that clofibrate
caused a significant increase in 20-HETE production
and Cyp4a expression in proximal tubular cells from wild-
type mice, but had no effect on Cyp4a expression in mice
with PPARa(/) (Figure 7). These results provide addi-
tional evidence that clofibrate induces the expression of
mouse Cyp4a isoforms through PPARa in the proximal
tubules.
It has been shown that 20-HETE, the major metabolite of
CYP-eicosanoids, has different actions on blood pressure
regulation. For example, 20-HETE formed in the renal
microvessels causes vasoconstriction leading to increasing
hypertensive mechanisms, whereas 20-HETE in renal tubules
inhibits sodium transport, thereby increasing natriuresis and
promoting antihypertensive mechanisms.1 These findings
point to the need to know whether or not the activation of
PPARa can induce Cyp4a expression in the vasculature. We
recently showed that chronic administration of clofibrate to
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rats fed a high-fat diet induces CYP4A expression in the
proximal tubules and TALH but not in renal microvessels.18
An earlier report showed that PPARa protein, which is highly
expressed in the proximal tubules and TALH, has very low
expression in preglomerular aterioles.32 Similarly, this study
demonstrated much higher expression levels of PPARa
protein in the proximal tubules than in renal microvessels
(Figure 4b). Even more to the point, Diep et al.36 found that
PPARa protein was undetectable in aortic and mesenteric
vascular smooth muscle cells. Taken together, these findings
suggest that the effects of activation of PPARa occur in
the endothelial cells of the vasculature and the tubular cells
of kidneys. This may be why the increase in 20-HETE
production in response to PPARa activation mainly occurs
in renal tubules rather than vascular sites, resulting in
antihypertensive mechanisms.
In summary, this study demonstrates that hypertension
induced by DOCA-salt is associated with sodium retention in
both wild-type mice and mice with PPARa(/). In both
strains, this sodium retention is associated with reduced renal
20-HETE production. Our findings also suggest that chronic
administration of clofibrate leads to increased renal Cyp4a
expression and 20-HETE production, changes that, in wild-
type mice treated with DOCA-salt, are associated with the
reduction of blood pressure and sodium retention. However,
we did not observe any of these effects of clofibrate in mice
with PPARa(/). As the DOCA-salt mouse mimics
hyperaldosteronism, this study raises the possibility that, in
addition to their lipid-lowering actions in dyslipidemic
patients, fibrate drugs may act as antihypertensive agents
against hyperaldosteronism.
MATERIALS AND METHODS
Animals
We performed uni-nephrectomy on 4-week-old male mice with
PPARa(/) (Jackson Laboratories, Bar Harbor, Maine, USA;
129S4/SvJae-Pparatm1Gonz/J) and wild-type control mice (Jackson
Laboratories, 129S1/SvImJ). After 1 week of recovery, mice with
PPARa(/) and wild-type mice were divided into the following
treatment groups: vehicle; DOCA (50 mg) and salt (1% NaCl and
0.1% KCl); and DOCA-salt plus clofibrate (500 mg/kg/day in corn
oil, intragastrically).
Direct blood pressure measurements
Mice with PPARa(/) (n¼ 9) and wild-type mice (n¼ 5) were
anesthetized with 2% isoflurane, after which a tapered polyethylene
catheter was placed in the femoral artery. Two days after catheter
placement, blood pressure was measured in freely moving mice by
means of pressure transducers coupled to a computer system
(EMKA Technologies, Falls Church, VA, USA).
Determination of sodium retention
We treated 5-week-old uni-nephrectomized male mice with
PPARa(/) (n¼ 5) and wild-type mice (n¼ 5) with vehicle,
DOCA-salt, or DOCA-salt plus clofibrate for 14 days. During
treatment, we kept these mice in individual metabolic cages. Sodium
balance was measured as sodium intake - urinary sodium excretion -
insensitive sodium loss, where sodium intake¼ (food weight food
[Na])þ (water intakewater [Na]), sodium excretion¼ urine
volume urine [Na], and insensitive sodium loss¼ average
intake minus average excretion during the first 6 days of measure-
ments. Cumulative sodium balance was calculated as described
previously.18,37
Primary proximal tubular cell culture
Ten wild-type mice or mice with PPARa(/) were killed for the
isolation of proximal tubules as described previously.38 We seeded
the purified proximal tubules into collagen-coated 10-cm dishes
in DMEM-F12 medium supplemented with 10% fetal bovine
serum, transferrin (5 mg/ml), insulin (3mg/ml), hydrocortisone
(5 10–8 mol/l), triiodothyronine (5 10–12 mol/l), 100mg/ml strepto-
mycin, and 100 U/ml penicillin. We maintained the culture flasks in
an incubator at 371C. We used passages 1–2 of proximal tubular cells
for the experiments.
Arachidonic acid (AA) metabolism in renal microsomes and
proximal tubular cells
Renal microsomes (250 mg) were incubated with [1-14C]-AA
(1.0 mCi, 17.5 nmol) and NADPH (1 mmol/l) in 0.6 ml potassium
phosphate buffer for 30 min at 371C. For primary proximal tubular
cells, we obtained four dishes of tubular cells (106 cells per dish)
from mice treated either with clofibrate (50 mmol/L) or vehicle
(0.02% DMSO). These cells were suspended in 4 ml of culture
medium, then incubated on ice for 15 min with 40 ml of 10% Tween-
80 and 0.2 mol/l EDTA. We then briefly centrifuged the cells and
washed them four times with 4 ml of phosphate buffer saline. After
suctioning away the buffer, we incubated the cells with NADPH
(1 mmol/l), 10 mM indomethacin, [1-14C]-AA (10mCi) in 0.5 ml
potassium phosphate buffer containing 10 mmol/l MgCl2 for 60 min
at 371C. AA metabolites were analyzed by HPLC as described
previously.39
Western blot analysis
Renal samples (10mg) from mice given different treatments were
separated by electrophoresis for 18 h. The proteins were transferred
to an enhanced chemiluminescence membrane in a transfer buffer.
The membranes were blocked for 90 min with 5% nonfat dry milk
in Tris-buffered saline. The membranes were incubated with rabbit
anti-rat CYP4A1 polyclonal antibody (1:2000; Abcam, Cambridge,
MA, USA) or rabbit anti-PPARa antibody (1:400; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The membranes were
incubated with secondary antibody for CYP4A1 and PPARa. The
immunoblots were developed using an enhanced chemilumines-
cence detection kit as previously described.18
Immunohistochemical analysis
Renal sections were cut on a cryostat at a thickness of 10 mm
and thawed onto glass slides. Specimens were fixed in cold acetone
for 10 min at 201C. We used diaminobenzidine to detect the
expression of Cyp4a isoforms. Nonspecific binding sites were
blocked by 2% normal rabbit serum in phosphate buffer saline,
whereas endogenous peroxidase activity was blocked by 0.9%
hydrogen peroxide in phosphate buffer saline for 1 h. Immunohis-
tochemical analysis was done as described previously.40
Quantitative real-time RT-PCR
Using a Nucleospin RNA II kit (Clontech, Mountain View, CA,
USA), total renal RNA was isolated from mice that were given
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different treatments. Total RNA (200 ng) was reverse-transcribed
using a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). The pre-developed
TaqMan gene expression assays for mouse Cyp4a isoforms were
purchased from Applied Biosystems. The analyses were performed
on an ABI 7500 Fast Real-Time PCR System (Applied Biosystems)
following the manufacturer’s recommended 2-step thermal
cycling program. During each extension step, oligonucleotide probes
with reporter and quencher dyes were degraded by 50-30 exonuclease
activity of Taq polymerase; the level of released reporter dye was
measured at the end of the cycle to determine the amount of
specific amplicon. The PCR amplification cycle at which the
reporter dye fluorescence passed the selected threshold (CT), was
calculated by the provided program. Expression of each Cyp4a
mRNA relative to 18S rRNA was calculated based on the change in
threshold cycle, in which DCT¼CT.targetCT.18S rRNA and normal-
ized between controls and each experimental treatment group,
expressed as –(DDCT).
28
Statistical analysis
Data are expressed as mean±s.e. All data were analyzed by SPSS
(Chicago, IL, USA) computer software. We used one-way ANOVA
or a Student’s unpaired two-tailed test for statistical analysis.
Statistical significance was set at Po0.05.
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